Long-acting HIV shot study aims to make prevention fairer for all

NCT ID NCT07620730

Not yet recruiting Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a long-acting injectable HIV prevention drug (cabotegravir) can be delivered fairly and effectively in NHS sexual health clinics. Researchers will follow 200 people taking the drug for 12 months, along with 20 healthcare professionals, to see how well it works in real-world settings and whether it reaches groups often underserved by current prevention options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: long-acting cabotegravir (LA CAB)
What this could lead to: If successful, this could show that long-acting injectable PrEP is a practical and equitable option for HIV prevention in the NHS, especially for underserved groups.
What could go wrong: This is an implementation study, not a test of the drug itself. It may reveal barriers that limit uptake or persistence, and results may not apply outside the UK.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMUNITY SETTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

posterior leukoencephalopathy syndrome HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMMUNITY SETTING EQUITY PREP PREP ADHERENCE EXPERIENCES PREP ADHERENCE PERSPECTIVES PREP UPTAKE

More trials for these conditions

Other studies related to the condition(s) this trial covers.